GLP-1 prescriptions for children surge over 30,000% since 2019

A medication class designed to treat adult diabetes has found its way into the hands of American children, and the pace of that shift has been startling. Between 2019 and now, prescriptions for GLP-1 drugs among kids under twelve have climbed more than 30,000 percent, according to a new study. The absolute numbers remain small—these medications are still uncommon in pediatric medicine—but the trajectory tells a story about how quickly medical practice can change when a drug gains cultural momentum.

GLP-1 receptor agonists, drugs like semaglutide and tirzepatide, were developed to help adults with type 2 diabetes manage blood sugar. In recent years they have become synonymous with weight loss, prescribed off-label to adults seeking to shed pounds, fueled by celebrity endorsements, social media visibility, and genuine clinical interest in obesity as a medical condition. The drugs work by slowing gastric emptying and signaling fullness to the brain. They have shown real efficacy in adults. They have also become culturally loaded—a symbol of both medical innovation and pharmaceutical excess, depending on who is talking.

Now that momentum has begun to reach children. Pediatricians are prescribing these medications to kids as young as eight years old, marking a significant departure from historical practice. A study examining this trend, attributed to NYU Langone Health researchers, found that while GLP-1 use in children remains rare in absolute terms, the rate of increase is undeniable. The baseline in 2019 was so low that even a small number of prescriptions today represents a multiplication by tens of thousands of percent.

The shift raises immediate questions that the medical community has not yet fully answered. These drugs have not been extensively studied in children. Their long-term effects on a developing body—on growth, on metabolic function, on the endocrine system—remain largely unknown. The medications were not designed for pediatric use. No one knows what happens when a child takes a GLP-1 drug for years, or what the appropriate dose should be, or at what age, if any, such treatment becomes justified. The FDA has approved semaglutide for weight management in adolescents twelve and older, but the prescriptions documented in this study include children younger than that.

Obesity in children is a genuine public health concern. Rates have climbed over decades. The health consequences are real—increased risk of type 2 diabetes, cardiovascular disease, and other chronic conditions. Parents and doctors facing a child with severe obesity are working within a system that offers few effective interventions. Behavioral approaches, dietary changes, and exercise programs have limited success rates. Surgery is an option for some adolescents but carries its own risks. Against that backdrop, a medication that works in adults becomes tempting, even if the evidence in children does not yet exist.

What remains unclear is how many children are actually receiving these prescriptions, which children they are, and whether they are being monitored for side effects. The study documents the trend but does not provide a complete picture of the clinical context. Are these prescriptions going to children with severe obesity and comorbid conditions? Are they being used as a first-line treatment or a last resort? Are families informed about the lack of long-term safety data? These details matter enormously for understanding whether this trend represents appropriate medical innovation or a concerning gap between clinical practice and evidence.

The story points toward a collision between medical need, pharmaceutical availability, and scientific uncertainty. As GLP-1 drugs continue to dominate cultural conversation and clinical attention, pediatricians will face increasing pressure to prescribe them. Families will ask for them. Insurance companies will develop policies around them. But the fundamental question—whether these drugs are safe and effective for children—remains largely unanswered. The next phase of this story will be written by researchers studying long-term outcomes, by regulators deciding what to approve, and by doctors deciding what to prescribe when a parent brings a child to the office and asks if this drug might help.